soybean oil
Trade name: Intralipid
Approved
Oct 7, 1975
Soybean oil is a vegetable oil extracted from soybean legumes. It is one of the most widely consumed cooking oils and the second most consumed vegetable oil. As a drying oil, processed soybean oil is also used as a base for printing inks and oil paints. — Wikipedia
Clinical trial activity
109 trials · 112 clinical orgs · 6 marketing orgs
Earliest trial started Mar 1, 2003 (NCT00892684)
Timeline
1970s
1980s
- Feb 26, 1982
Baxter — NDA Secondary Org
- Jun 29, 1983
Alpha Therapeutic Corporation — NDA Secondary Org
- Aug 27, 1984
Hospira — NDA Secondary Org
- Aug 19, 1985
Baxalta — NDA Secondary Org
1990s
- May 28, 1993
B. Braun — NDA Secondary Org
2000s
Indications
Studied for
- Abortion, Habitual · Phase 4
- Abortion, Spontaneous · Phase 4
- Aging · Phase 1
- Anesthesia · Phase 4
- Atrial Fibrillation · Phase 3
- Blood Pressure · Early Phase 1
- Cardiovascular Diseases · Phase 2/Phase 3
- Child Nutrition Disorders · Phase 4
- Cholestasis · Phase 4
- Cognition Disorders · Phase 1/Phase 2
- Craniocerebral Trauma · Phase 2
- Crohn Disease · Phase 4
- Depression · Phase 2/Phase 3
- Diabetes Mellitus, Type 2 · Phase 4
- Drug-Related Side Effects and Adverse Reactions · Phase 2
- Enteral Nutrition · Phase 2
- Esophageal Atresia · Phase 2
- Fatty Acids · Phase 4
- Fatty Acids, Omega-3 · Phase 2
- Gastroschisis · Phase 2
- General Surgery · Phase 4
- Healthy Volunteers · Phase 4
- Hematopoietic Stem Cell Transplantation · Phase 1
- Hemorrhoids · Phase 4
- Hypertension · Phase 4
- Ileus · Phase 4
- Infant, Premature · Phase 4
- Infant, Premature, Diseases · Phase 4
- Infertility · Phase 4
- Inflammation · Phase 4
- Insulin Resistance · Phase 2/Phase 3
- Intestinal Atresia · Phase 2
- Intestinal Diseases · Phase 3
- Intestinal Failure · Phase 2
- Intestinal Neoplasms · Phase 3
- Kernicterus · Phase 2
- Kidney Diseases · Phase 1
- Malnutrition · Phase 4
- Metabolic Diseases · Phase 2/Phase 3
- Metabolic Syndrome · Phase 4
- Mood Disorders · Phase 2/Phase 3
- Myocardial Ischemia · Phase 3
- Neoplasms · Phase 4
- Obesity · Phase 2
- Organophosphate Poisoning · Phase 2/Phase 3
- Pancreatic Neoplasms · Phase 4
- Parenteral Nutrition · Phase 4
- Pediatrics · Phase 2/Phase 3
- Pregnancy Complications · Phase 4
- Psychomotor Disorders · Phase 4
- Reperfusion Injury · Phase 2/Phase 3
- Respiratory Distress Syndrome · Phase 2
- Short Bowel Syndrome · Phase 2
Mechanism of action
- UnclearUnclear
Unclear unclear
Combination products
clinolipi
with olive
kabiven
with potassium chloride, magnesium sulfate, sodium acetate, amino acids, sodium glycerophosphate pentahydrate, calcium chloride, glucose monohydrate
Also known as perikabiven
liposyn ii
with safflower oil
smoflipi
Approval history
- approvedOct 7, 1975
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaSoybean oil ↗
- NCATS241ATL177A ↗
- ChEMBLCHEMBL1201485 ↗
- WikipediaLipid emulsion ↗
Also known as
- intrafat
- intralipid
- intralipid
- intralipid
- intralipid
- lipofundin
- lipofundin
- liposyn iii
- liposyn iii
- liposyn iii
- nutrilipid
- soyacal
- soy bean oil
- soybean oil
- soybean oil
- soybean oil
- soybean oil
- soybean oil, phospholipid emulsion
- travamulsion
- travamulsion
- travamulsion
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06736925 | Phase 2 | Jan 31, 2025 | Indiana University, National Institute of Neurological Disorders and Stroke (NINDS) |
| NCT06625372 | N/A | Oct 12, 2024 | Shahid Beheshti University of Medical Sciences |
| NCT05553405 | Phase 1 | Jan 1, 2023 | Yale University |
| NCT05199948 | N/A | May 2, 2022 | Ohio State University |
| NCT04832009 | Early Phase 1 (Phase 1) | Jan 1, 2022 | University of Kansas |
| NCT04975763 | N/A | Jul 19, 2021 | Ohio State University |
| NCT04807634 | N/A | Mar 10, 2021 | Ain Shams University |
| NCT04466618 | Phase 3 | Dec 31, 2020 | Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| NCT04555044 | Phase 4 | Nov 19, 2020 | Baxalta |
| NCT04584983 | Phase 2 | Nov 1, 2020 | University of Texas at Houston |
| NCT04806425 | Phase 4 | Oct 1, 2020 | Ain Shams University |
| NCT04558190 | N/A | Sep 2, 2020 | University of Copenhagen |
| NCT04328337 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2020 | Yale University |
| NCT04393103 | Phase 2/Phase 3 (Phase 3) | May 31, 2020 | Assiut University |
| NCT04274803 | Phase 4 | Apr 1, 2020 | Tanta University |
| NCT04120220 | N/A | Nov 30, 2019 | United States Department of Agriculture |
| NCT04242004 | Phase 1/Phase 2 (Phase 2) | Oct 30, 2019 | Fudan University |
| NCT03998709 | Phase 4 | Oct 1, 2019 | Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| NCT04084522 | N/A | Sep 30, 2019 | Institute of Liver and Biliary Sciences, India |
| NCT04067323 | N/A | Sep 8, 2019 | National Institute of Nutrition, Vietnam |
Organizations
Research & Development (112)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Emory University | Academic/Hospital | 6 | 6 | 3 | 2004 |
| Ain Shams University | Academic/Hospital | 5 | 4 | 4 | 2012 |
| Harvard University | Academic/Hospital | 5 | 4 | 3 | 2006 |
| University of Toronto | Academic/Hospital | 5 | 5 | 4 | 2004 |
| Baxalta | For profit | 4 | 2 | 2 | 2008 |
| B. Braun | For profit | 4 | 4 | 3 | 2006 |
| Fresenius | For profit | 4 | 2 | 3 | 2009 |
| Mayo Clinic | Academic/Hospital | 4 | 4 | 3 | 2018 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 4 | 0 | 3 | 2008 |
| Assiut University | Academic/Hospital | 3 | 3 | 2 | 2012 |
| Cairo University | Academic/Hospital | 3 | 2 | 2 | 2012 |
| American Diabetes Association | Academic/Hospital | 2 | 0 | 1 | 2004 |
| Indiana University | Academic/Hospital | 2 | 2 | 2 | 2018 |
| Institute of Liver and Biliary Sciences, India | Academic/Hospital | 2 | 2 | 1 | 2016 |
| Jiao Tong University | Academic/Hospital | 2 | 2 | 1 | 2012 |
| National Center for Complementary and Integrative Health (NCCIH) | Government | 2 | 0 | 2 | 2008 |
| Office of Dietary Supplements (ODS) | Government | 2 | 0 | 2 | 2008 |
| Ohio State University | Academic/Hospital | 2 | 2 | 1 | 2021 |
| Radboud University | Academic/Hospital | 2 | 2 | 2 | 2005 |
| United States Department of Agriculture | Government | 2 | 2 | 1 | 2015 |
Marketing (9)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Alpha Therapeutic Corporation | For profit | NDA2 | Jun 29, 1983 |
| B. Braun | For profit | NDA2 | May 28, 1993 |
| Baxalta | For profit | MKTG | Oct 3, 2013 |
| Baxalta | For profit | NDA2 | Aug 19, 1985 |
| Baxter | For profit | NDA2 | Feb 26, 1982 |
| Fresenius | For profit | MKTG | Aug 25, 2014 |
| Fresenius | For profit | NDA2 | Oct 7, 1975 |
| Fresenius | For profit | NDA | Oct 7, 1975 |
| Hospira | For profit | NDA2 | Aug 27, 1984 |